An observational study in Chronic Ulcers: Non-healing Deep Cavity Wounds (e.g., Diabetic Foot Ulcers, Arterial Ulcers, Post-surgical Wound Healing Disorders), sponsored by Barbara Wolff-Winiski. Not yet recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-04.
Sponsored by Barbara Wolff-Winiski · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies in Diabetic Foot with a site in Germany — 4 open to participants now, 4 under way, none of them phase 3. Diabetic Foot · Germany.
Among the 37 studies in Diabetic Foot with a site in Germany, this one is one of 2 that started in 2026, is one of 8 observational ones, and was the 36th registered.
1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.
Browse Diabetic Foot studies →4 of the 37 studies in Diabetic Foot with a site in Germany are open now. Recruiting first, the newest first:
Cutempa Medical AG · Sites in Germany
Ages 18+
Heinrich-Heine University, Duesseldorf · Sites in Germany
Ages 18+
VULM s.r.o. · Sites in Germany, Poland
Ages 18–85
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 139 Diabetic Foot studies recruiting now, 98 (71%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 10 · Phase 3 11 · Phase 4 1
First in 2002; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 72 is below the median of 100 across 191 observational studies indexed under Diabetic Foot.
Median enrollment 136 across the 29 interventional studies, 89 across the 8 observational. Of the 29 that completed or were terminated, 11 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 37 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Barbara Wolff-Winiski as lead sponsor.
Barbara Wolff-Winiski has 1 study filed under Diabetic Foot — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 37 studies in Diabetic Foot with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective observational study will collect routine clinical waste material from 72 adults with chronic, non-healing wounds, including wound exudate from negative pressure therapy containers or sponges and wound biofilm/debridement material. Samples and routine clinical wound data will be used to test INJECTHEAL hydrogel components and other wound healing therapeutics, and identify molecular, biochemical, and microbiological biomarkers linked to wound healing.
The Horizon Europe project INJECTHEAL platform is designed to provide a biomimetic matrix for tissue regeneration and to enable controlled delivery of antibacterial, anti-inflammatory, and pro-angiogenic components.
This is a monocentric, prospective, exploratory, non-interventional observational study. It involves the collection of biological material and health-related personal data from adults with chronic, non-healing deep cavity wounds who are treated as part of routine clinical care. Study data will be documented in doubly pseudonymized form.
Biological material will consist of routine clinical waste material. Wound exudate will be obtained from negative pressure wound therapy and biofilm/debridement material will be collected from medically indicated sharp or surgical debridement. Where feasible, longitudinal sampling will be performed during routine wound care visits, with approximately 3 to 5 visits expected per participant.
Components of the INJECTHEAL hydrogel system and other wound healing therapeutics will be evaluated for their capacity to mitigate or reverse inhibitory effects of chronic wound material on regenerative cellular functions.
Further analyses will include biochemical and molecular characterization of wound exudates, including total protein, proteases and protease activity, growth factors, cytokines, proteomic profiles, and metabolomic profiles. Biofilm samples will be analyzed using microbiological and molecular methods, including bacterial rRNA16S metagenomic sequencing and patient-specific 3D biofilm models to assess antibacterial effects of INJECTHEAL components.
Adults with chronic, non-healing deep cavity wounds, such as diabetic foot ulcers, arterial ulcers of the lower extremity, post-surgical non-healing wounds, or wounds with delayed healing, who are treated as part of routine clinical care and who undergo routine negative pressure wound therapy and/or medically indicated sharp or surgical debridement.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: standard of care
Patients enrolled in this observational study receive standard of care. Treatment, ointments, compression and bandages will be registered at every visit.
Wound Exudate and Biofilm Extract Effects on Proliferation of Primary Human Fibroblasts
Proliferation (Optical density)
Time frame: Four weeks
Antibacterial Effects of INJECTHEAL Components on Patient-Specific 3D Wound Biofilm Samples
Bacterial growth (Colony forming units)
Time frame: Four weeks
Effects of Wound Material and Test Substances on Cell Migration
Cellular migration (Percent surface area covered)
Time frame: Four weeks
Effects of Wound Exudate and/or Biofilm Extracts on Proliferation of Additional Wound-Relevant Cell Types
Proliferation (Optical density)
Time frame: Four weeks
Pro-Inflammatory Cytokine Secretion in Wound-Relevant Cell Types
Measurement of pro-inflammatory cytokines (ng/ml)
Time frame: Four weeks
Protein content of wound exudate
Quantification of total protein (mg/ml)
Time frame: Four weeks
Proteomics profile of wound exudate
Proteomics analysis of wound exudate (-log10(p-value))
Time frame: Four months
Bacterial composition of wound biofilm by rRNA16S sequencing
Bioburden, Diversity and Pathogens
Time frame: Four weeks
Correlation of ex vivo/in vitro, biochemical, proteomic, metabolomic, and microbiological findings with routinely collected clinical data
Correlation of laboratory findings with clinical wound trajectory
Time frame: Four weeks
Effects of Wound Material and Test Substances on Extracellular Matrix Formation
Extracellular Matrix Formation (Optical density)
Time frame: 4 weeks
Inflammatory Marker Response in Wound-Relevant Cell Types
Inflammatory markers (Mean fluorescence intensity)
Time frame: 4 weeks
Metabolomics profile of wound exudate
Metabolomics analysis of wound exudate (Ion counts)
Time frame: 4 months
Protease acitivty
Proteases (nM)
Time frame: 4 weeks
Plan to share: Yes — Individual patient data can be shared anonymized upon contact with PI, after publication of primary results.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Data will be avaiable after publication of primary results.
Access criteria: Access upon request via email to Principal Investigator.
Start is estimated for Aug 2026; primary completion for Apr 2028, 20 months later.
Of 90 observational studies under Diabetic Foot, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 59. This study's planned 20 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.